On May 23, 2024 Novocure (NASDAQ: NVCR) reported topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany (Press release, NovoCure, MAY 23, 2024, View Source [SID1234643652]). The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine clinical care completed to date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Median overall survival for patients treated with TTFields therapy was 19.6 months (95% CI, 17.9-22.4). Median progression-free survival was 10.2 months (95% CI, 9.4-11.4). TTFields therapy use was not associated with an increase in systemic toxicity and was well tolerated. The outcomes observed in the TIGER study are consistent with the survival and safety results from Novocure’s phase 3 EF-14 clinical trial.

Patients were followed for a median duration of 56.2 months. One-, two-, three-, and four- year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively.

"As TTFields therapy use becomes more prevalent around the globe, it is exciting to see large, prospective studies like TIGER corroborate the survival benefits provided by using TTFields therapy to treat newly diagnosed GBM," said Oliver Bähr, MD, Department of Neurology, General Hospital Aschaffenburg-Alzenau. "The outcomes observed, particularly long-term survival rates, are promising and make a compelling case that TTFields therapy should be presented to all eligible GBM patients."

"TIGER is the largest prospective, non-interventional study analyzing TTFields therapy use in newly diagnosed GBM completed to date," said Nicolas Leupin, MD, Novocure’s Chief Medical Officer. "The observations from TIGER contribute to the multitude of data validating the use of TTFields therapy, and we are eager to continue exploring the benefits of our therapy in both the clinical and real-world settings."

The TIGER data (abstract #2036) will be presented at 9:00 a.m. CDT on Saturday, June 1, 2024 in Hall A during the Central Nervous System Tumors session at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.

About TIGER

TIGER (NCT03258021) is a prospective, non-interventional, multicenter, medical device post-authorization study designed to obtain real life data on the use of Tumor Treating Fields (TTFields) therapy in patients with newly diagnosed glioblastoma in routine clinical care in Germany. 710 patients with histologically confirmed newly diagnosed glioblastoma, who had clinical indication for TTFields therapy and were within the first 3 cycles of maintenance chemotherapy treatment were enrolled in the study from August 2017 to November 2019, across 81 participating centers in Germany. 583 patients opted to use TTFields therapy, and 429 received treatment. Endpoints of the study included overall survival, progression-free survival, safety and quality of life.

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.